Clinical Trials Logo
  1. Home
  2. Toxicity, Drug
  3. NCT04499885
  4. Details
NCT04499885 Clinical Trial

Potential Role of Gastric Lavage by Paraffin Oil in Acute Aluminum Phosphide Poisoning

Toxicity, Drug Clinical Trial

Official title:
Potential Role of Gastric Lavage by Paraffin Oil in Acute Aluminum Phosphide Poisoning: A Randomized Controlled Clinical Trial

Clinical Trial Details — Status: Recruiting

Administrative data
NCT number NCT04499885
Other study ID # ghada protocol
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date June 1, 2020
Est. completion date December 10, 2030

Study information
Verified date August 2020
Source Tanta University
Contact Sherief Abd-Elsalam, ass. prof.
Phone 00201147773440
Email sheriefabdelsalam@yahoo.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Potential Role of Gastric Lavage by Paraffin Oil in Acute Aluminum Phosphide Poisoning.

Description:

The study aims to investigate the Potential Role of Gastric Lavage by Paraffin Oil in Acute Aluminum Phosphide Poisoning: A Randomized Controlled Clinical Trial

Recruitment information / eligibility
Status Recruiting
Enrollment 62
Est. completion date December 10, 2030
Est. primary completion date December 1, 2030
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Inclusion Criteria:

- • Patients with symptomatic acute aluminum phosphide poisoning

Exclusion Criteria:

- • Pregnant and lactating women

- Asymptomatic patients with history of acute aluminum phosphide exposure.

- Patients with ingestion or exposure to other substances in addition to aluminum phosphide.

- Patients with other major medical conditions (e.g. cardiovascular disease, renal or hepatic failure).

- Patients with previous medical intervention (had gastric lavage in any medical center before admission).

- Patients with disturbed consciousness level

- Patients with post cardiac arrest cases

Study Design

Related Conditions & MeSH terms

Intervention

Device:
• Paraffin oil gastric lavage
Gastric lavage will be initiated with 50 mL of Paraffin oil and 50 mL of sodium bicarbonate solution
• Gastric lavage with saline and sodium bicarbonate 8.4%
Gastric lavage with saline and sodium bicarbonate 8.4%

Locations
Country Name City State
Egypt Sherief Abd-Elsalam Tanta

Sponsors (1)
Lead Sponsor Collaborator
Sherief Abd-Elsalam

Country where clinical trial is conducted

Egypt, 

Outcome
Type Measure Description Time frame Safety issue
Primary Number of deaths The number of deaths 6 months
See also
  Status Clinical Trial Phase
Completed NCT04916392 - Observation Study of the Pharmacokinetics of Adductor Canal Block
Completed NCT04260113 - Apatinib for Inoperable Advanced Chondrosarcoma N/A
Recruiting NCT05355168 - Neoadjuvant Chemoradiotherapy Combined With Camrelizumab and Nimotuzumab for Esophageal Squamous Cell Carcinoma Phase 1/Phase 2
Recruiting NCT04351308 - Comparison of MAPI+Camrelizumab Versus API+Apatinib Versus MAPI in Patients With a Poor Response to Preoperative Chemotherapy for Newly Diagnosed High-grade Osteosarcoma Phase 2
Active, not recruiting NCT03638375 - TIL and Anti-PD1 in Metastatic Melanoma Phase 1/Phase 2
Recruiting NCT05652673 - Safe Stop Ipilimumab-nivolumab (IPI-NIVO) Trial N/A
Recruiting NCT05512169 - Pharmacogenomic Association Study in Indian Children With Acute Lymphoblastic Leukemia
Completed NCT04690231 - Apatinib + Ifosfamide and Etoposide for Relapsed or Refractory Osteosarcoma N/A
Completed NCT02719002 - Studying the Performance of OCT C-scan in the Screening for Retinopathy Related to Synthetic Antimalarials N/A
Suspended NCT04824352 - Apatinib Plus IE Chemotherapy (Ifosfamide and Etoposide) for Relapsed or Refractory Osteosarcoma Phase 2